Skip to Content
Merck
  • Vasorelaxing effect of U50,488H in pulmonary artery and underlying mechanism in rats.

Vasorelaxing effect of U50,488H in pulmonary artery and underlying mechanism in rats.

Life sciences (2005-12-13)
Xin Sun, Sai Ma, Yi-Min Zang, Shun-Yan Lu, Hai-Tao Guo, Hui Bi, Yue-Min Wang, Heng Ma, Xin-Liang Ma, Jian-Ming Pei
ABSTRACT

To investigate the relaxation effect and underlying mechanism of U50,488H (a selective kappa-opioid receptor agonist) in pulmonary artery in the rat. Isolated pulmonary artery ring was perfused and the tension of the vessel was measured. U50,488H relaxed the pulmonary artery ring in a dose-dependent manner and the effect was abolished by nor-binaltorphimine, a selective kappa-opioid receptor antagonist. The relaxation effect of U50,488H in pulmonary artery was partially endothelium-dependent and was significantly attenuated in the presence of L-NAME. The relaxation effect of U50,488H was significantly attenuated by K(V) channel blocker 4-AP (4-aminopyridine), but not by glibenclamide (ATP-sensitive K+ channel blocker) nor TEA (tetraethylamonium, Ca2+-activated K+ channel blocker). Further study also showed that endothelium denudation and 4-AP have an additive inhibitory effect on pulmonary artery relaxation caused by U50,488H. Kappa-opioid receptor activation by U50,488H relaxes pulmonary artery via two separate pathways: one is endothelium-derived nitric oxide, the other is K(V) channel in pulmonary artery smooth muscle.